BioVie Inc. - Common stock (BIVI) analyst actions
Rating and price-target actions on BIVI in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the BIVI overview →
3 measured BIVI analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson’s Disease with First Patient Enrolled | Press release | -2.78% | -3.27% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioVie Inc. (BIVI) And Encourages Shareholders to Reach Out | Press release | +1.34% | -8.07% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioVie Inc. (BIVI) And Encourages Stockholders to Reach Out | Press release | +3.19% | +9.57% |
Keep exploring
More BIVI: earnings → · SEC filings → · BIVI overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| TESARO (TSRO) | 804 | -0.14% | 47% |
| SYNERGY PHARMACEUTICALS (SGYP) | 803 | -0.38% | 41% |
| Sanofi - American Depositary Shares (SNY) | 798 | +0.02% | 52% |
| Cerecor, Inc (CERC) | 795 | -0.03% | 43% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.